Monitor for future equity grants under the new plan, which could signal management's confidence or need for retention. The evergreen provision may lead to gradual dilution of ~5% annually. No immediate trading catalyst.
Price Chart
Executive Summary
Verrica Pharmaceuticals filed an 8-K reporting that stockholders approved the Amended and Restated 2018 Equity Incentive Plan at the 2026 Annual Meeting, adding 1,756,257 new shares plus an evergreen provision for annual increases. The filing also reports the election of directors Paul B. Manning and Lawrence Eichenfield, advisory approval of executive compensation, and ratification of KPMG as auditor. This is a routine administrative filing with no material financial impact.
Key Facts
- Stockholders approved the Amended and Restated 2018 Equity Incentive Plan on June 5, 2026, with 11,142,881 votes for, 433,852 against, and 36,469 abstentions.
- The plan adds 1,756,257 new shares to the share reserve, plus an evergreen provision increasing the reserve by 5% of outstanding shares annually from 2027 to 2036.
- Directors Paul B. Manning and Lawrence Eichenfield were elected with 11,543,142 and 11,523,540 votes for, respectively.
- Advisory vote on named executive officer compensation passed with 11,564,256 votes for, 34,355 against.
- KPMG LLP was ratified as independent auditor for FY 2026 with 14,058,234 votes for.
- 14,069,331 shares (81.89% of outstanding) were present or represented at the meeting.
Financial Impact
No financial figures reported; equity plan adds up to 1,756,257 new shares plus annual evergreen increases, but no immediate dilution or cash impact.
Risk Factors
- Potential dilution from future equity awards under the expanded plan.
- No financial data provided to assess current business performance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-263722 |
| Document: d139416d8k.htm | 0001193125-26-263722 |
| Document: 0001193125-26-263722-index-headers.html | 0001193125-26-263722 |
| Document: 0001193125-26-263722-index.html | 0001193125-26-263722 |
| Document: 0001193125-26-263722.txt | 0001193125-26-263722 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 6w ago | Press Release | $4.95 $4.18 | ▼ −15.56% | ▼ −17.68% | $3.36 (−32.12%) |
Jun 9, 2026 19w ago | 8-K | $5.75 $6.53 | ▲ +13.57% | ▲ +9.94% | $3.36 (−41.57%) |
May 12, 2026 23w ago | 8-K | $7.37 $6.03 | ▼ −18.25% | ▼ −17.64% | $3.36 (−54.41%) |
May 12, 2026 23w ago | Press Release | $7.37 $6.03 | ▼ −18.25% | ▼ −17.64% | $3.36 (−54.41%) |
Apr 20, 2026 27w ago | DEFA14A | $6.32 $5.87 | ▼ −7.12% | ▼ −12.04% | $3.36 (−46.84%) |
Mar 11, 2026 32w ago | Press Release | $6.26 $5.83 | ▼ −6.87% | ▼ −7.39% | $3.36 (−46.33%) |
Mar 4, 2026 33w ago | Court Ruling | $5.20 $5.47 | ▼ −5.19% | ▼ −8.67% | $3.36 (+35.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers